Back to search

Peptide record

TPDB06910

Antibacterial Anticancer Toxicity standard
12 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB06910
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia
standard
No
A 12-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.
Sequence
RWKIFKKAAKKA
Physicochemical Analysis
C71H119N21O13
NDCEQGHLMPSTYV
K
1474.86
11.85
6
0
6
+6
1.96
-1.017
57.50
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
5500
372.92
0
Residue Composition
number
3
A
1
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
1
I
0
L
5
K
0
M
1
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 3 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 0 K: 5 M: 0 F: 1 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
12
C71H119N21O13
1474.86
11.85
+6
1.96
-1.017
Evidence Records 3 records
Evidence 1 Activity

Activity

0% Killing
Toxicity
50 µM
Cytotoxic
0% Killing | 50 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Development of a novel short 12-meric papiliocin-derived peptide that is effective against Gram-negative sepsis. | Sci Rep | 2019
Evidence 2 Activity

Activity

0% Killing
Toxicity
50 µM
Cytotoxic
0% Killing | 50 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Development of a novel short 12-meric papiliocin-derived peptide that is effective against Gram-negative sepsis. | Sci Rep | 2019
Evidence 3 Activity

Activity

10% hemolysis
Toxicity
200 µM
Hemolytic Cytotoxic
10% hemolysis | 200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Development of a novel short 12-meric papiliocin-derived peptide that is effective against Gram-negative sepsis. | Sci Rep | 2019